There has been much recent interest in the mitochondrial diseases such as Kearns only, is that improvement occurs as a result of the impaired viability of muscle fibres containing large numbers of defective mitochondria.5 Negative selection against mitochondria with deleted genomes may be more intense than it is against those with duplications. 3 This paper discusses recent clinical and genetic studies of mitochondria and mitochondrial disease, and proposes an explanation of the clinical features of those cases of MtD produced by defects of the mtDNA. This hypothesis does not apply to those mitochondrial disorders caused by defects in the nuclear genome. However, this model accounts for the tissue distribution of MtD, the great clinical variation of disease both within and between families, and the evolutionary tendency for mitochondrial genes to be transferred to the nuclear genome. In addition, several predictions are made that are potentially falsifiable.
Disease model
The central hypothesis is that some defects of mtDNA give a selective advantage to their mitochondrial lineage. It has been clear for many years that defective mitochondria accumulate in the MtMs, to produce the 'ragged red fibres': that they accumulate selectively in the fibres with the lowest cytochrome c oxidase activity, in this class of myopathy, has also been known for some time. (i) Muscle tissue: is regularly subject to metabolic stress that must be accentuated in areas with defective mitochondria. This is true whether the muscle is using glycogen or fatty acids. Tissues with a blood supply sufficient to prevent anaerobic metabolism under usual circumstances will be less prone to mitochondrial disease.
(ii) Central nervous system: requires functioning mitochondria to use the non-glucose fuels such as ketone bodies that are especially important in infancy and during periods of fasting. Defective mitochondria will therefore be at a replicative advantage during infancy, and also during spells of relative hypoglycaemia/fasting later in life, and will predispose to CNS dysfunction. The localised lactic acidosis that would be maximal in certain areas within the brain could also cause transient dysfunction or permanent damage from cell necrosis, and hence produce the MELAS (mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes) or MERRF (myoclonus, epilepsy, and ragged red fibres) syn- The accumulation of mtDNA mutations in muscle and other tissues with advancing age has been proposed as an important contributor to ageing and degenerative disease.27 Certainly, mitochondrial function has been shown to decline with age in 'healthy' subjects.28 While the advocates of this hypothesis cite the high mutation rate in mtDNA and the lack of a repair system as supporting evidence, I would add that positive selection in favour of new mutation mtDNA defects could occur, rather than their passive accumulation and random segregation between cells. This would naturally accelerate the process of senescence: perhaps mega-doses of ascorbic acid will prove to be beneficial after all! EVOLUTION Mitochondria and chloroplasts have most probably evolved from prokaryotic endosymbionts of the early eukaryotes. This helps to explain the resemblance of the transcription and translation systems of these organelles to those of bacteria. The mitochondrial genome of unicellular eukaryotes is larger, and codes for more RNA and protein species than does the mitochondrial genome of man. Thus, yeast mtDNA (78 kb) includes several genes for tRNAs and proteins (some as yet unidentified) that are not found in the smaller (17 kb) human mtDNA. The explanation of this is that the short and long term interests of the yeast mitochondria are identical to those of the whole organism. This is not true of man: the short term interests of defective mitochoncria in man can be contrary to their own long term interests, and those of the 'host' organism (the patient with MtD).
Once multicellular organisms developed tissues whose metabolic activities differed substantially, the possibility of mitochondrial disease will have arisen.
This will have resulted in selection in favour of the transfer of many functions of the mtDNA into the nucleus. Why this process is not complete, why the mitochondrial genome still exists in man, is not clear. Perhaps the mitochondria have retained little more DNA than is required for them to coordinate their own replication, although we do not know how this is achieved. Alternatively, the existence of multiple copies of the mtDNA dispersed in the cell may be advantageous, and the slight differences between the genetic triplet codes of organelle and nucleus may have made the successful transfer of certain genes to the nucleus into an improbability.
Another evolutionary consequence of the transfer ofmtDNA sequences to the nucleus is that populations and species will differ in the functions remaining to the mitochondrial genome. Interspecies hybrids may then be viable, because at least one copy of each gene will be present in the nucleus, but may also be infertile. This would arise if the two species' mtDNAs had lost different genes to the nucleus, because many of the offspring would then inherit some such genes from neither parent. There could, on this model, be differential infertility, depending upon which species had provided the hybrid's mother. Could this effect be important in determining the infertility of interspecies hybrids?
PREDICTIONS AND POSSIBLE THERAPIES This model of mitochondrial evolution and disease permits certain extrapolations to be made (concerning cases in which the defect is in the mtDNA).
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